{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:04:47Z","timestamp":1789538687503,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In many countries, Assisted Reproductive Technology (ART) remains funded predominantly out-of-pocket, with no private insurance reimbursement and only limited public provision. For many individuals, the cost of a single ART cycle may exceed monthly income, rendering treatment financially inaccessible. Therefore, even modest differences in medication costs can meaningfully influence treatment initiation and cycle completion<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Given the limited regional evidence and the need for context-specific economic evaluations in Latin America, the present study aims to evaluate the economic impact of using Corifollitropin Alfa (CFA), a long-acting gonadotropin, compared with daily recombinant FSH for controlled ovarian stimulation (COS) in ART treatments in Brazilian women, under the assumption of equivalent clinical effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cost-minimization analysis was conducted from a Brazilian private-sector, out-of-pocket patient perspective, following national and international guidelines for healthcare economic evaluations. Medication reference prices, including taxes, were obtained from the official Brazilian regulatory database as of May 2025. Sensitivity analyses were performed to evaluate different gonadotropin dosing strategies in standardized COS protocols for women aged 35\u201342 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across all scenarios tested, CFA was consistently associated with substantial cost reductions compared with daily rFSH. Assuming the equipotency between a single injection of CFA 150\u2005\u00b5g and rFSH 300 IU\/day for the first 7 days of COS, CFA plus follitropin alfa versus follitropin alfa alone reduced the pharmacological cost by approximately 52.1%. Similarly, CFA plus follitropin beta showed a reduction of approximately 56.3% in medication costs when compared to follitropin beta alone. These findings remained robust across all sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CFA was associated with substantial pharmacological cost savings of more than 50% when compared to follitropin alfa or follitropin beta, assuming that a single injection of CFA 150\u2005\u00b5g is equipotent to daily injections of rFSH 300 IU for the first 7 days of COS. Although further real-world studies are needed to validate and expand on these findings, this analysis provides meaningful evidence to support patient-centered decision-making and healthcare planning in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frph.2026.1939114","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:49Z","timestamp":1789536709000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting"],"prefix":"10.3389","volume":"8","author":[{"given":"G. N.","family":"Cecchino","sequence":"first","affiliation":[{"name":"Mater Prime and Mater Lab","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Bruno Ramalho Reprodu\u00e7\u00e3o Humana , Bras\u00edlia, Brazil"},{"name":"Faculdade de Ci\u00eancias da Educa\u00e7\u00e3o e da Sa\u00fade, Curso de Medicina, Centro Universit\u00e1rio de Bras\u00edlia - CEUB","place":["Bras\u00edlia, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ramires","sequence":"additional","affiliation":[{"name":"Government Relations, Access and Communication","place":["Organon, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L. P.","family":"Bueno","sequence":"additional","affiliation":[{"name":"Government Relations, Access and Communication","place":["Organon, Brazil"]},{"name":"Researcher at Escola Nacional de Administra\u00e7\u00e3o P\u00fablica, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Lucio","sequence":"additional","affiliation":[{"name":"Medical Affairs","place":["Organon, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. P.","family":"Santana","sequence":"additional","affiliation":[{"name":"Medical Affairs","place":["Organon, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105216","DOI":"10.1016\/j.rbmo.2025.105216","article-title":"Assisted reproductive technology in Latin America: the Latin American registry, 2022","volume":"52","author":"Zegers-Hochschild","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"B2","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104413","DOI":"10.1016\/j.rbmo.2024.104413","article-title":"Assisted reproductive technologies in Latin America: the Latin American registry, 2021","volume":"50","author":"Zegers-Hochschild","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"B4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12958-015-0131-z","article-title":"A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey","volume":"13","author":"Audibert","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.rbms.2018.01.001","article-title":"Comparative economic study of the use of corifollitropin alfa and daily rFSH for ovarian stimulation in older patients: cost-minimization analysis based on the PURSUE study","volume":"5","author":"Barrenetxea","year":"2018","journal-title":"Reprod Biomed Soc Online"},{"key":"B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.fertnstert.2015.04.018","article-title":"Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist ovarian stimulation protocol in older patients undergoing in vitro fertilization","volume":"104","author":"Boostanfar","year":"2015","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104987","DOI":"10.1016\/j.rbmo.2025.104987","article-title":"A single dose of corifollitropin alfa is equipotent to a daily dose of 300 IU recombinant FSH regardless of ovarian reserve","volume":"51","author":"Garc\u00eda-Velasco","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1093\/humrep\/dep291","article-title":"A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol","volume":"24","author":"Devroey","year":"2009","journal-title":"Hum Reprod"},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rbmo.2010.03.019","article-title":"Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women","volume":"21","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"B10","first-page":"132","volume-title":"Diretrizes Metodol\u00f3gicas: Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica","year":"2014"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clinthera.2022.01.011","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B12","year":"2025"},{"key":"B13","year":"2020"},{"key":"B14","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.medre.2017.01.003","article-title":"El uso de la corifolitropina alfa en donantes de \u00f3vulos obtiene la misma eficiencia reproductiva y efectividad que la FSH recombinante, con una mayor comodidad para la donante","volume":"4","author":"Calatayud","year":"2017","journal-title":"Med Reprod Embriol Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.rbmo.2017.03.003","article-title":"Economic impact of controlled ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study","volume":"34","author":"Cruz","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/humrep\/der139","article-title":"Willingness to pay and conjoint analysis to determine women's Preferences for ovarian stimulating hormones in the treatment of infertility in Spain","volume":"26","author":"Palumbo","year":"2011","journal-title":"Hum Reprod"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1472-6483(10)60271-4","article-title":"Understanding the burden of ovarian stimulation: fertility expert and patient perceptions","volume":"19","author":"Huisman","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/0167482X.2012.752810","article-title":"Developing and testing a new instrument to measure women's Satisfaction with controlled ovarian stimulation treatment","volume":"34","author":"Roca de Bes","year":"2013","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.rbmo.2012.11.015","article-title":"Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin \u03b1","volume":"26","author":"Requena","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"B21","volume-title":"Infertility is a Disease and a Public Health Issue","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.rbms.2016.04.001","article-title":"Long-term fiscal implications of funding assisted reproduction: a generational accounting model for Spain","volume":"1","author":"Matorras","year":"2015","journal-title":"Reprod Biomed Soc Online"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.fertnstert.2013.01.145","article-title":"Time costs of fertility care: the hidden hardship of building a family","volume":"99","author":"Wu","year":"2013","journal-title":"Fertil Steril"},{"key":"B24","doi-asserted-by":"publisher","year":"","DOI":"10.1007\/s10815-017-0952-0"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2026.1939114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:50Z","timestamp":1789536710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2026.1939114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":24,"alternative-id":["10.3389\/frph.2026.1939114"],"URL":"https:\/\/doi.org\/10.3389\/frph.2026.1939114","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1939114"}}